Company and Industry Summary Company Overview - **Company Name**: 乐普生物 (Lepu Biopharma) - **Industry**: Biopharmaceuticals Key Financial Metrics for 2025 - **Total Revenue**: 9.35 billion CNY, a 150% increase from 3.68 billion CNY in 2024 [3] - **Net Profit**: 259 million CNY, marking the first annual profit since listing; adjusted net loss narrowed to 30 million CNY after excluding a one-time gain of 289 million CNY [2][3] - **Operating Cash Flow**: Net outflow reduced to 12 million CNY, achieving near cash flow balance [3] - **Cash and Equivalents**: 853 million CNY, doubled from 401 million CNY in 2024 [3] - **R&D Expenses**: 401 million CNY, down 8.5% year-on-year [3][4] - **Sales Expense Ratio**: 47%, with a commercial net profit margin of 39% [3] Commercialization and Product Development - **Key Products**: - **PD-1 Product (普佑恒)** and **EGFR ADC (美佑恒)**: Combined sales of 501 million CNY in 2025, with a gross margin of 86% [2][3] - **MRG003 (EGFR ADC)**: Approved for nasopharyngeal carcinoma, showing an objective response rate (ORR) of 73.3% in clinical trials [5] - **CMG901 (Claudin18.2 ADC)**: Global phase III trial for gastric cancer ongoing, with data expected in H1 2026 [6] - **MRG007 (CDH17 ADC)**: Phase I data to be presented at ESMO 2026 [7] Pipeline and Clinical Trials - **MRG004A (TF-targeted ADC)**: Phase III trial initiated for pancreatic cancer, aiming for NDA submission [7] - **CG0,070 (Oncolytic Virus)**: Phase III data shows a complete response rate of 75% in high-risk bladder cancer patients [8] - **MRG006A (GPC3-targeted ADC)**: Ongoing phase II trials, with plans for combination therapy in liver cancer [9] Strategic Focus and Future Plans - **New Molecules**: Two new molecules targeting EGFR/CD54 and PD-1/LILRB2 expected to enter IND in 2026, focusing on overcoming tumor resistance [10][11] - **Sales Strategy for MRG003**: Aiming for over 800 million CNY in sales in 2026, with plans to negotiate inclusion in medical insurance [11][12] - **Market Expansion**: Exploring applications of MRG003 in non-small cell lung cancer and other indications [12] Milestones and Financial Outlook - **Milestone Payments**: Expected to contribute significantly to cash flow, with CMG901 and MRG007 being key projects [14][20] - **Profitability Outlook**: Confidence in maintaining profitability in 2026 and 2027, supported by product sales and BD projects [19][20] Additional Insights - **Market Potential**: CMG901's broader patient coverage compared to existing therapies indicates significant market opportunity [6] - **Clinical Development Strategy**: Focus on differentiating therapies in competitive markets, particularly in pancreatic and gastric cancers [18] This summary encapsulates the key points from the conference call, highlighting the company's financial performance, product pipeline, strategic initiatives, and market outlook.

Market Overview - The CITIC Medical Index decreased by 2.52%, underperforming the CSI 300 Index by 1.45 percentage points, ranking 14th among 30 primary industries [9] - The top ten stocks by increase this week include Yahu Medicine-U, New Harmony, Zhejiang Medicine, and others, with increases ranging from 10.42% to 15.24% [9] Industry Insights and Investment Themes - **Innovative Drugs**: China has seen a high-quality growth in the number of therapies under research, significantly outpacing the global average. The total overseas licensing amount for domestic new drugs surpassed $10 billion for the first time in 2021, indicating a robust market share for Chinese innovative drugs [12] - **Medical Devices**: 1. The pressure from centralized procurement of high-value consumables is easing, allowing for continued development and value reassessment in the industry [12] 2. The scale of medical equipment bidding in China is showing signs of recovery, with a revenue inflection point expected by Q3 2025 [12] 3. The IVD sector is experiencing a gradual clearance of policy disruptions, enhancing local market penetration [12] 4. Leading domestic manufacturers of low-value consumables are upgrading their product lines to create new growth momentum [12] 5. Emerging technologies like AI in healthcare and brain-machine interfaces are expected to drive industry transformation [12] - **Pharmaceutical Supply Chain (CXO + APIs)**: Domestic CXO companies are seeing a good performance in front-end orders, which is expected to gradually translate into earnings, heralding a new wave of innovation in the pharmaceutical supply chain [12] - **Life Sciences Services**: The industry demand is recovering, with domestic substitution deepening and overseas expansion continuing, leading to a positive revenue outlook starting from Q4 2024 [12] - **Traditional Chinese Medicine**: The market for essential medicines is expected to see significant growth, especially for unique essential medicines, while state-owned enterprise reforms are anticipated to enhance fundamentals [12] - **Pharmacies**: The sector is expected to benefit from prescription outflow and market optimization, with a notable shift towards online and offline integration [12] - **Medical Services**: The negative impact of medical reform policies is nearing its end, with the sector expected to return to a growth trajectory as the macroeconomic environment improves [12] - **Blood Products**: The approval of plasma stations is becoming more lenient, opening up further growth opportunities in the industry [12] Electrophysiology Industry Update - The demand for electrophysiology devices is expected to grow due to an increase in patients with rapid arrhythmias, driven by global aging [16] - The market for electrophysiology devices is projected to expand significantly, with the global market expected to reach $7.9 billion by 2025 and $20.1 billion by 2034, reflecting a CAGR of 11.0% [16] - In China, the electrophysiology device market is expected to grow from 15.7 billion yuan in 2025 to 42 billion yuan by 2032, with a CAGR of 15.1% [16] - The number of patients with rapid arrhythmias in China is projected to reach 28.2 million by 2024, highlighting the critical need for effective treatment options [16] - Catheter ablation is recognized as the first-line therapy for rapid arrhythmias, offering advantages such as minimal invasiveness and effective outcomes [16] Competitive Landscape - The electrophysiology market in China is still largely dominated by international giants like Johnson & Johnson, Abbott, and Boston Scientific, indicating significant room for domestic manufacturers to grow [19] - Domestic companies such as Huatai Medical and Microelectrophysiology are making strides in technology innovation and product upgrades, gradually increasing their market share [19] - The market for electrophysiology mapping products is expected to see increased competition, with domestic firms gaining ground in various segments [19] Product Development and Regulatory Landscape - The approval rate for electrophysiology mapping devices has slowed, but the proportion of domestic products is increasing [24] - The introduction of advanced technologies such as AI-assisted mapping and integrated mapping and ablation functions is expected to enhance the efficiency and effectiveness of electrophysiology procedures [24] - The regulatory environment is becoming more favorable for domestic manufacturers, facilitating the introduction of innovative products to the market [19]

Investment Rating - The report gives a "Buy" rating for the company, indicating a positive outlook for its stock performance in the next 12 months [4]. Core Insights - The approval of the clinical trial application (IND) for MRG006A, a novel ADC drug targeting GPC3 for advanced liver cancer, marks a significant advancement in precision treatment for liver cancer [1]. - MRG006A is the first GPC3-targeted ADC to enter clinical trials globally, with GPC3 being highly expressed in 70%-80% of hepatocellular carcinoma cases, making it a promising target for therapy [1]. - The company has a strong pipeline with multiple first-in-class (FIC) drugs and has achieved breakthrough therapy designations for several candidates, positioning it well in the ADC and immunotherapy landscape [4][3]. Financial Projections - Revenue projections for the company are as follows: 368 million RMB in 2024, 944 million RMB in 2025, and 1.428 billion RMB in 2027, with growth rates of 63.2%, 156.5%, and 44.4% respectively [5]. - The net profit attributable to the parent company is expected to improve from a loss of 411 million RMB in 2024 to a profit of 89 million RMB in 2027 [5]. - Earnings per share (EPS) are projected to transition from -0.23 RMB in 2024 to 0.05 RMB in 2027, reflecting a significant turnaround [5]. Product Pipeline and Market Position - The company has a diverse product pipeline that includes two commercialized ADCs and eight candidates in clinical stages, with a focus on unmet clinical needs in liver and pancreatic cancers [3]. - MRG003, the first approved EGFR-targeted ADC in China, and MRG004A for advanced pancreatic cancer are notable products in the pipeline, with ongoing clinical trials [3]. - The company has successfully licensed two ADCs to international partners, indicating strong market potential and a successful "go global" strategy [3].

Investment Rating - The report initiates coverage with a "Buy" rating for Lepu Biopharma (2157.HK) [4] Core Insights - Lepu Biopharma's ADC drug MRG006A has received approval for clinical trials, marking a significant step towards precision treatment for liver cancer [1] - MRG006A is the first GPC3-targeted ADC to enter clinical trials globally, with potential to address unmet clinical needs in liver cancer treatment [1][2] - The company has a strong pipeline with multiple ADC products and has successfully commercialized two drugs, indicating a leading position in the ADC market [3] Financial Projections - Expected revenues for Lepu Biopharma are projected to be 368 million RMB in 2024, 944 million RMB in 2025, and 1.428 billion RMB in 2027, with growth rates of 63.2%, 156.5%, and 44.4% respectively [5] - The net profit attributable to the parent company is forecasted to be -411 million RMB in 2024, -35 million RMB in 2025, and 89 million RMB in 2027, indicating a turnaround by 2027 [5] - Earnings per share (EPS) are expected to improve from -0.23 RMB in 2024 to 0.05 RMB in 2027 [5] Product Pipeline and Market Position - Lepu Biopharma's product pipeline includes 8 clinical candidates, with 6 being ADC products, showcasing a robust focus on innovative therapies [3] - The company has successfully licensed two ADCs internationally, with significant financial agreements, indicating strong market confidence [3] - MRG006A and MRG007 are developed based on the next-generation Hi-TOPi ADC platform, which is expected to enhance the company's value [3]

Summary of the Conference Call for Lepu Biopharma (2157.HK) Company Overview - Lepu Biopharma is focused on the development of innovative cancer therapies, particularly in the areas of immunotherapy, antibody-drug conjugates (ADC), and oncolytic virus drugs. The company has a robust pipeline and is expected to enter a period of new drug approvals in the next 3-5 years [1][2]. Key Points R&D Pipeline and Drug Approvals - The company has developed multiple oncology product lines, including: - PD-1 monoclonal antibody, Pralsetinib, and MRG003, which are already on the market. - Six ADC drugs, one oncolytic virus, and one T cell engager (TCE) drug currently in clinical stages. - The overall pipeline is well-structured, indicating a promising future for new drug approvals [1][2]. Financial Performance - The company has achieved its first profitability and positive operating cash flow in the first half of 2025, driven by business development (BD) and sales efforts [2]. Competitive Advantages of ADCs 1. **MRG003 (EGFR ADC)**: - Approved for use in late-line nasopharyngeal carcinoma (NPC) in China, showing superior survival benefits and safety compared to competitors. - Actively pursuing broader indications in head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC), with a Phase III trial ongoing for 2L+ HNSCC [2][3]. 2. **MRG004A (TF-ADC)**: - Currently in Phase III trials for late-line pancreatic cancer, demonstrating strong competitive potential [3]. 3. **MRG006A (GPC3 ADC)**: - A first-in-class (FIC) targeting the liver cancer market, with promising results from Phase I trials, and expected to enter Phase III trials in 2026 [3]. 4. **CMG901**: - A global FIC CLDN 18.2 ADC, currently in Phase III trials [3]. 5. **MRG001 (CD20 ADC)**: - Showing potential in diffuse large B-cell lymphoma (DLBCL) [3]. Oncolytic Virus Therapy - The company introduced the oncolytic virus therapy CG0070 in 2019, targeting the bladder cancer market. - CG0070 has initiated a rolling Biologics License Application (BLA) with the FDA for high-risk non-muscle invasive bladder cancer (NMIBC) and is in critical registration bridging trials in China. - Recent Phase III data indicates historical best durability in NMIBC, with a G3+ treatment-related adverse event (TRAE) rate of 0, showcasing both efficacy and safety [3]. International Expansion - The company has successfully collaborated on international projects with MRG007 (CDH17 ADC) and CTM012 (a tri-antibody targeting CD3/4-1BB/DLL3) [3]. Revenue Projections - Revenue forecasts for the company are as follows: - 2025: 880 million CNY - 2026: 1.02 billion CNY - 2027: 1.49 billion CNY - Expected growth rates are 138% in 2025, 16% in 2026, and 47% in 2027, with net profits projected at -20 million CNY in 2025, 10 million CNY in 2026, and 280 million CNY in 2027 [3]. Investment Rating - The company’s ADC pipeline is progressing steadily, and commercial advancements are on track, leading to a "Buy" rating [4]. Risk Factors - Potential risks include: - Delays in clinical progress of innovative drugs. - Subpar clinical data for innovative drugs. - Poor sales performance post-launch of innovative drugs. - Geopolitical risks [4].

Core Viewpoint - The company is entering a new drug approval phase with a well-structured pipeline in oncology, focusing on immunotherapy, ADC targeted therapy, and oncolytic virus drugs, which is expected to yield multiple new drug approvals in the next 3-5 years [1][2]. Pipeline Development - The company has developed multiple oncology products, including two already marketed drugs (PD-1 monoclonal antibody Prutilizumab and MRG003) and has six ADC drugs, one oncolytic virus, and one TCE drug in clinical stages [1]. - MRG003 (EGFR ADC) has been approved for post-line NPC in China, showing superior survival benefits and safety compared to competitors, with ongoing trials for HNSCC and NSCLC [1]. - MRG004A (TF-ADC) for post-line pancreatic cancer is currently in Phase III trials after demonstrating strong competitive advantages in Phase I [2]. - MRG006A (GPC3 ADC) is targeting the liver cancer market, with promising results in Phase I trials and plans to initiate Phase III trials in 2026 [1][2]. Oncolytic Virus Therapy - The company has introduced the oncolytic virus therapy CG0070 for bladder cancer, which is currently undergoing a rolling BLA application with the FDA and is in critical registration bridging trials in China [2]. - CG0070 has shown the best historical durability efficacy data in the NMIBC field, with a G3+TRAE rate of 0, indicating excellent efficacy and safety [2]. Financial Projections - The company is still in the investment phase for innovative drug development, with projected revenues of 880 million, 1.02 billion, and 1.49 billion yuan for 2025, 2026, and 2027, respectively, representing year-on-year growth of 138%, 16%, and 47% [2]. - The net profit attributable to the parent company is expected to be -20 million, 10 million, and 280 million yuan for the same years [2]. Investment Recommendation - The company is rated as a "buy" due to the steady progress of its ADC pipeline and successful commercialization efforts [2].

Investment Rating - The report assigns a "Buy" rating for the company, Lepu Biopharma (2157.HK), marking its first coverage [1]. Core Insights - The company is entering a harvest period for new drug approvals, having established a comprehensive pipeline in oncology that includes immunotherapy, ADC (Antibody-Drug Conjugate) targeted therapy, and oncolytic virus drugs. The company has multiple ADC drugs and other therapies in clinical stages, with expectations for new drug approvals in the next 3-5 years [3][10]. - The ADC pipeline is characterized by unique features and competitive advantages in various indications, with MRG003 (EGFR ADC) already approved for NPC (nasopharyngeal carcinoma) in China and showing promising results in other indications [4][30]. - The introduction of oncolytic virus therapy CG0070 has shown potential in the bladder cancer market, with successful regulatory progress in the U.S. and ongoing clinical trials in China [5][30]. - Financially, the company has achieved its first profit and positive operating cash flow in the first half of 2025, with steady revenue growth driven by business development and sales [25]. Summary by Sections R&D Coverage and Pipeline - The company focuses on oncology treatment, with a pipeline that includes immunotherapy, ADCs, and oncolytic virus therapies. It has developed a robust ADC technology platform and has multiple products in various stages of clinical development [11][10]. - The pipeline includes 6 ADC drugs and 1 oncolytic virus therapy, with several candidates in pivotal clinical stages, indicating a well-structured development strategy [14][10]. Unique Features of ADCs - MRG003 has been approved for NPC and is in advanced trials for HNSCC (head and neck squamous cell carcinoma) and NSCLC (non-small cell lung cancer), showcasing its broad applicability and competitive edge [30][4]. - Other ADCs in development, such as MRG004A for pancreatic cancer and MRG006A for liver cancer, are also progressing well, with MRG004A entering pivotal trials [30][6]. Financial Performance and Projections - The company reported revenues of 4.66 billion yuan in the first half of 2025, a significant increase from 1.33 billion yuan in the same period of 2024. The net profit for the same period was 290 million yuan, marking a turnaround from a loss of 197 million yuan in the previous year [25][30]. - Revenue projections for 2025, 2026, and 2027 are estimated at 8.8 billion yuan, 10.2 billion yuan, and 14.9 billion yuan, respectively, with expected growth rates of 138%, 16%, and 47% [30].

Investment Rating - The report initiates coverage with an "Outperform" rating for Lepu Biopharma-B (2157) [4] Core Views - The company is a leading domestic innovative pharmaceutical enterprise focusing on ADC combined with IO in oncology, with expectations for rapid market penetration following the approval of MRG003 [1][4] - The product pipeline is expected to expand internationally, indicating strong long-term growth potential for the company [1] Financial Summary - Projected total revenue for 2024A, 2025E, 2026E, and 2027E is 368 million, 853 million, 1,204 million, and 1,665 million RMB respectively, reflecting growth rates of 63%, 132%, 41%, and 38% [3] - Gross profit is expected to increase from 292.97 million in 2024A to 1,415.20 million in 2027E, with a gross margin projected to be around 79.66% to 85% [3] - Net profit is forecasted to improve from -411 million in 2024A to -29 million in 2027E, indicating a significant reduction in losses [3] Company Overview - Lepu Biopharma was established in January 2018 and focuses on oncology, particularly targeted and immunotherapy [9] - The company has built a diverse product pipeline through acquisitions and partnerships, including PD-1 antibodies and ADCs [9] - The management team is experienced, with a high concentration of ownership, ensuring stability and strategic direction [13][15] Market Potential - The global and Chinese cancer immunotherapy market is expected to grow significantly, with a CAGR of 16.3% and 25.1% respectively from 2025 to 2030 [28][31] - The PD-1 therapy market in China is projected to reach 582 billion RMB by 2030, with a CAGR of 30.5% from 2020 to 2025 [33][35] ADC Market Growth - The global ADC market is anticipated to reach 66.2 billion USD by 2030, with a CAGR of 30.3% from 2023 to 2030 [41] - The ADC market in China is expected to grow at a CAGR of 72.6% from 2023 to 2028, reaching 38.3 billion RMB [44][45] Product Pipeline and Clinical Development - MRG003 is currently under NDA review and has shown promising results in clinical trials for R/M NPC, with a significant improvement in overall response rates compared to chemotherapy [56][61] - The company is actively exploring combination therapies with PD-1 inhibitors, which may enhance treatment efficacy [60][65]

Investment Rating - The report assigns an "Accumulate" rating to the company [5]. Core Insights - The company is a leading domestic innovative pharmaceutical enterprise focusing on ADC combined with IO, with expectations for rapid growth following the approval of MRG003 [2]. - The product pipeline includes plans for international business development, indicating a positive long-term outlook for the company [2]. Financial Summary - Projected total revenue for 2024A is 368 million RMB, with a growth rate of 63%. By 2027E, revenue is expected to reach 1,665 million RMB, with a growth rate of 38% [4]. - The company is projected to achieve a net profit of -411 million RMB in 2024A, improving to -29 million RMB by 2027E [4]. - The price-to-earnings (PE) ratio is expected to improve from -10.04 in 2024A to -389.49 in 2027E, while the price-to-book (PB) ratio is projected to increase from 5.87 to 18.86 over the same period [4]. Company Overview - The company was established in January 2018 and focuses on innovative treatments for cancer, particularly targeted therapies and immunotherapies [13]. - The company has built a robust product pipeline through acquisitions and partnerships, including PD-1 antibodies and ADC drugs [13][15]. - The management team is experienced, with a high concentration of ownership, ensuring stability and strategic direction [15][19]. Market Potential - The global and Chinese cancer immunotherapy market is expected to grow significantly, with a projected CAGR of 16.3% and 25.1% respectively from 2025 to 2030 [30]. - The PD-1 therapy market in China is anticipated to reach 582 billion RMB by 2030, with a CAGR of 30.5% from 2020 to 2025 [33]. Product Pipeline and Development - The company has multiple tumor product pipelines covering immunotherapy, ADC targeted therapy, and oncolytic virus drugs [20]. - MRG003 is currently under NDA review for treating R/M NPC, with potential for significant market impact [22]. - The company is also exploring combination therapies with PD-1 antibodies, which may enhance treatment efficacy [20]. Sales Growth - The company's first commercial product, the PD-1 antibody, has seen rapid sales growth, achieving 300 million RMB in revenue in 2024, three times the revenue of 2023 [23][36]. - The company has expanded its sales network across 118 cities in China, enhancing its market presence [36].

Core Viewpoint - The 18A companies in the Hong Kong stock market have experienced a significant turnaround in 2025, showcasing a surge in listings, stock price increases, and international expansion opportunities [1][2][4]. Listing Wave - In 2025, there has been a notable wave of listings for 18A companies, with 10 out of 58 newly listed companies being 18A firms, many of which performed exceptionally well on their debut [2]. - The enthusiasm from investors is evident, with companies like Zhonghui Biotechnology and Yinnuo Pharmaceutical experiencing over 4000 times and 5341 times oversubscription, respectively [2]. - There are currently 49 18A companies that have submitted applications to the Hong Kong Stock Exchange, with at least 20 awaiting approval for listing [2][4]. Price Surge - Among the 77 listed 18A companies, 17 have seen stock price increases exceeding 200%, while 26 have risen between 100% and 200% since the beginning of 2025 [5]. - Beihai Kangcheng has recorded the highest increase at 1644%, although its total market capitalization remains relatively small at approximately 1.1 billion HKD [5][6]. International Expansion - The 18A companies are leveraging unique "outbound" strategies by licensing their products to well-known overseas pharmaceutical companies, which enhances their revenue potential and showcases their technological advancements [7]. - For instance, Rongchang Biotechnology has licensed its RC28-E injection to Santen China for a total of 2.5 billion HKD in upfront payments and additional milestone payments [8]. - The trend of outbound licensing is indicative of the rapid progress of Chinese pharmaceutical companies, transitioning from imitation to innovation, and establishing a competitive edge in the global market [9][10].